A MVA construct expressing a secretable form of the Dengue virus 3 envelope protein protects immunized mice from dengue-induced encephalitis

Bárbara R. Quinan; Alice Freitas Versiani; Flávio G. da Fonseca

doi:10.1016/j.vaccine.2016.10.058

A MVA construct expressing a secretable form of the Dengue virus 3 envelope protein protects immunized mice from dengue-induced encephalitis

Bárbara R. Quinan, Alice Freitas Versiani, Flávio G. da Fonseca

Research output: Contribution to journal › Article › peer-review

Abstract

Dengue is no longer restricted to tropical developing countries, but is now a major global public health problem. Despite the recent license approval of the CYD-TDV vaccine in some countries, efforts to develop a more efficient vaccine against Dengue virus (DENV) continue. Herein, we evaluate the immunogenicity and level of protection of two potential vaccines against DENV based on recombinant modified vaccinia virus Ankara (rMVA). The vaccine addressing the Envelope protein from DENV serotype 3 to the endoplasmic reticulum elicited neutralizing antibodies titers which correlate with protection, and also confers protection upon challenge in a mouse model. Our results support the development of a tetravalent dengue vaccine with the further construction of rMVAs expressing proteins from the other DENV serotypes.

Original language	English (US)
Pages (from-to)	6120-6122
Number of pages	3
Journal	Vaccine
Volume	34
Issue number	50
DOIs	https://doi.org/10.1016/j.vaccine.2016.10.058
State	Published - Dec 7 2016
Externally published	Yes

Keywords

Dengue vaccine
Encephalitis model
MVA
Neutralizing antibodies
Recombinant MVA

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2016.10.058

Cite this

@article{9824fc14845b40fdaeffe87cd2e6b07d,

title = "A MVA construct expressing a secretable form of the Dengue virus 3 envelope protein protects immunized mice from dengue-induced encephalitis",

abstract = "Dengue is no longer restricted to tropical developing countries, but is now a major global public health problem. Despite the recent license approval of the CYD-TDV vaccine in some countries, efforts to develop a more efficient vaccine against Dengue virus (DENV) continue. Herein, we evaluate the immunogenicity and level of protection of two potential vaccines against DENV based on recombinant modified vaccinia virus Ankara (rMVA). The vaccine addressing the Envelope protein from DENV serotype 3 to the endoplasmic reticulum elicited neutralizing antibodies titers which correlate with protection, and also confers protection upon challenge in a mouse model. Our results support the development of a tetravalent dengue vaccine with the further construction of rMVAs expressing proteins from the other DENV serotypes.",

keywords = "Dengue vaccine, Encephalitis model, MVA, Neutralizing antibodies, Recombinant MVA",

author = "Quinan, {B{\'a}rbara R.} and Versiani, {Alice Freitas} and {da Fonseca}, {Fl{\'a}vio G.}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Ltd",

year = "2016",

month = dec,

day = "7",

doi = "10.1016/j.vaccine.2016.10.058",

language = "English (US)",

volume = "34",

pages = "6120--6122",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "50",

}

TY - JOUR

T1 - A MVA construct expressing a secretable form of the Dengue virus 3 envelope protein protects immunized mice from dengue-induced encephalitis

AU - Quinan, Bárbara R.

AU - Versiani, Alice Freitas

AU - da Fonseca, Flávio G.

PY - 2016/12/7

Y1 - 2016/12/7

N2 - Dengue is no longer restricted to tropical developing countries, but is now a major global public health problem. Despite the recent license approval of the CYD-TDV vaccine in some countries, efforts to develop a more efficient vaccine against Dengue virus (DENV) continue. Herein, we evaluate the immunogenicity and level of protection of two potential vaccines against DENV based on recombinant modified vaccinia virus Ankara (rMVA). The vaccine addressing the Envelope protein from DENV serotype 3 to the endoplasmic reticulum elicited neutralizing antibodies titers which correlate with protection, and also confers protection upon challenge in a mouse model. Our results support the development of a tetravalent dengue vaccine with the further construction of rMVAs expressing proteins from the other DENV serotypes.

AB - Dengue is no longer restricted to tropical developing countries, but is now a major global public health problem. Despite the recent license approval of the CYD-TDV vaccine in some countries, efforts to develop a more efficient vaccine against Dengue virus (DENV) continue. Herein, we evaluate the immunogenicity and level of protection of two potential vaccines against DENV based on recombinant modified vaccinia virus Ankara (rMVA). The vaccine addressing the Envelope protein from DENV serotype 3 to the endoplasmic reticulum elicited neutralizing antibodies titers which correlate with protection, and also confers protection upon challenge in a mouse model. Our results support the development of a tetravalent dengue vaccine with the further construction of rMVAs expressing proteins from the other DENV serotypes.

KW - Dengue vaccine

KW - Encephalitis model

KW - MVA

KW - Neutralizing antibodies

KW - Recombinant MVA

UR - http://www.scopus.com/inward/record.url?scp=84998546810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998546810&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2016.10.058

DO - 10.1016/j.vaccine.2016.10.058

M3 - Article

C2 - 27817963

AN - SCOPUS:84998546810

SN - 0264-410X

VL - 34

SP - 6120

EP - 6122

JO - Vaccine

JF - Vaccine

IS - 50

ER -

A MVA construct expressing a secretable form of the Dengue virus 3 envelope protein protects immunized mice from dengue-induced encephalitis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this